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Abstract
Background: Overall gastric cancer survival remains poor mainly because there are no reliable methods for
identifying highly curable early stage disease. Multi-protein profiling of gastric fluids, obtained from the anatomic
site of pathology, could reveal diagnostic proteomic fingerprints.
Methods:  Protein profiles were generated from gastric fluid samples of 19 gastric cancer and 36 benign
gastritides patients undergoing elective, clinically-indicated gastroscopy using surface-enhanced laser desorption/
ionization time-of-flight mass spectrometry on multiple ProteinChip arrays. Proteomic features were compared
by significance analysis of microarray algorithm and two-way hierarchical clustering. A second blinded sample set
(24 gastric cancers and 29 clinically benign gastritides) was used for validation.
Results: By significance analysyis of microarray, 60 proteomic features were up-regulated and 46 were down-
regulated in gastric cancer samples (p < 0.01). Multimarker clustering showed two distinctive proteomic profiles
independent of age and ethnicity. Eighteen of 19 cancer samples clustered together (sensitivity 95%) while 27/36
of non-cancer samples clustered in a second group. Nine non-cancer samples that clustered with cancer samples
included 5 pre-malignant lesions (1 adenomatous polyp and 4 intestinal metaplasia). Validation using a second
sample set showed the sensitivity and specificity to be 88% and 93%, respectively. Positive predictive value of the
combined data was 0.80. Selected peptide sequencing identified pepsinogen C and pepsin A activation peptide as
significantly down-regulated and alpha-defensin as significantly up-regulated.
Conclusion: This simple and reproducible multimarker proteomic assay could supplement clinical gastroscopic
evaluation of symptomatic patients to enhance diagnostic accuracy for gastric cancer and pre-malignant lesions.
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Background
Unlike other common cancers, the prognosis for most
gastric cancer patients is poor and has improved little over
the past several decades. Five-year survival rates for gastric
cancer are considerably lower than all major cancers
except cancers of the liver, pancreas and esophagus [1].
Given that early stage gastric cancer has a much better
prognosis (5-year survival approximately 90%) than
advanced gastric cancer (5-year survival 3–10%) [2,3],
global mortality from gastric cancer ought to decrease
substantially by measures that result in downstaging of
tumors at the time of initial diagnosis.
Although gastroscopy is the gold standard for gastric can-
cer diagnosis, its accuracy is not as high as it is for benign
gastric diseases such as peptic ulcers, especially in geo-
graphic regions of low to intermediate gastric cancer prev-
alence. The percentage of missed cancer diagnosis,
reported as 4.6%, 14% and even 33% [4-6], is not insig-
nificant. Even in Japan, the false negative rate was
reported to be 19% [7]. These data are consistent with the
positive predictive value of only 0.4 – 0.7 for endoscopic
diagnosis of gastric cancer in different centers [8-10].
Although the proportion of missed diagnoses appears
small, the absolute number of patients denied the benefit
of diagnosis at a curable stage is not negligible. Even at a
modestly low false positive diagnostic rate of 5%, more
than 47,000 gastric cancers would have been missed in
one low prevalence country alone (USA) in a single year,
2000 [11]. Endoscopic assessment frequently includes
mucosal biopsies but there are no clinical standards for
either the optimal number of biopsies or the anatomic
regions that should be sampled. A commonly cited rec-
ommendation is to take at least seven biopsies to correctly
diagnose gastric cancer [12]. In this study however, fully
17% of all lesions subsequently shown to be malignant
were considered benign on endoscopy. Thus, endoscopic
mucosal examination suffers from inter-observer varia-
tion, suboptimal correlation with histopathology, diffi-
culty in detecting submucosal cancers and unimpeded
visualization of all anatomic sub-regions e.g. after previ-
ous gastric surgery [13,14].
Gastric fluid consists of a mixture of secreted soluble and
exfoliated cellular proteins from the entire gastric mucosa
– including regions that cannot be adequately assessed by
fibreoptic gastroscopy. We therefore reasoned that the
proteomic profile of gastric fluid, usually regarded as a
waste by-product during gastroscopic examination, could
usefully supplement conventional clinical evaluation by
providing a 'molecular biopsy' that effectively samples the
entire gastric mucosa, especially as protein detection tech-
niques such as mass spectrometry can be highly sensitive.
If performed during the course of clinically indicated gas-
troscopy, obtaining gastric fluid does not increase the
invasiveness of the procedure. Unlike the plasma pro-
teome, the gastric fluid proteome is likely to be less com-
plex but enriched in disease-specific biomarkers, being
generated directly at the disease site. The same biomark-
ers, even if present in plasma, may be diluted beyond the
limits of detection and admixed with other more abun-
dant systemic proteins that reflect concurrent pathophys-
iologic conditions (e.g. co-morbid diseases), rather than
anatomic site-specific disease.
We have investigated a novel approach to developing
biomarkers for gastric cancer by profiling soluble secreted
peptides present in endoscopically aspirated gastric fluid
and proteins extracted from exfoliated epithelial cells, also
recovered during endoscopy by surface-enhanced laser
desorption-ionization time-of-flight (SELDI TOF) mass
spectrometry. Our results suggest that multiple protein
biomarkers from an organ-specific source i.e. gastric fluid,
generate a distinctive gastric cancer signature that merits
further development as a tool for improving the diagnos-
tic accuracy of gastroscopy and has potential for detecting
early stage gastric cancer and pre-malignant lesions (intes-
tinal metaplasia and dysplasia).
Methods
Clinical samples
Gastric fluids were obtained during gastroscopy of over-
night fasted patients seen at the Singapore General Hospi-
tal. The study protocol was approved by the Ethics
Committee of the Singapore General Hospital. and con-
formed to the provisions of the Declaration of Helsinki
1995. Indications for gastroscopy were solely clinical and
were independent of the study. Initial analysis was per-
formed on a training set of 19 samples from histologically
proven gastric adenocarcinomas (13 intestinal type, 4 dif-
fuse type, 1 mixed type, 1 indeterminate) [15] and 36
samples from patients with clinically benign gastric con-
ditions. The mean age of 19 gastric cancer patients (13
male, 6 female; 17 Chinese, 2 Indian) was 68 years. Dis-
tribution by American Joint Committee on Cancer (AJCC)
clinical staging was stage 0 (1 patient), stage I (4 patients),
stage II (2 patients), stage III (2 patients) and stage IV (10
patients). The mean age of 36 patients with benign gastric
conditions (19 male, 17 female; 33 Chinese, 2 Malay, 1
Indian) was 57 years. Clinical diagnoses after endoscopy
of non-cancer patients were normal (9), antral gastritis
(9), gastritis (6), ulcer (4), hiatal hernia (3), hyperplastic
polyps (2), Barrett's esophagus (1), fundic scar (1) and
adenomatous polyp (1).
The classification algorithm developed from the training
set was tested by blinded analysis of a validation set con-
sisting of another 24 histologically confirmed gastric ade-
nocarcinomas (10 intestinal type, 7 diffuse type, 1 mixed
type, 5 indeterminate, 1 neuroendocrine) and 29 clini-BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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cally benign gastric samples. The mean age of these 24 gas-
tric cancer patients (18 males, 6 females; 21 Chinese, 3
Malay) was 70 years. Distribution by AJCC clinical staging
was stage I (5 patients), stage II (4 patients), stage III (2
patients) and stage IV (12 patients). One patient in the
validation set declined further investigation and could not
be staged. The mean age of 29 non-cancer patients (11
male, 18 female; 26 Chinese, 2 Indian, 1 Malay) was 47
years. Clinical diagnoses after gastroscopy of non-cancer
patients were gastritis (14), fundic gland polyps (2), acute
gastric ulcer (2), duodenitis (2), hiatal hernia (1) and nor-
mal (8).
None of the gastric cancer patients had received any form
of cancer treatment at the time of gastroscopy.
Taking training and validation cases together, 19% (8/43)
and 29% (19/65) of patients with gastric cancer and
benign gastric conditions, respectively, were positive for
H. pylori, a difference that was not significant by Fisher's
exact test (2-sided p value = 0.4508).
Sample collection and processing
Gastric fluid was aspirated into a sterile container at com-
mencement of endoscopy, assigned an anonymised code
and immediately placed on ice. Blood- or bile-stained
samples were rejected. Only clinically suspicious mucosal
lesions were biopsied at the discretion of the endoscopist.
Gastric fluids were centrifuged at 180 g for 6 minutes at
4°C, from which the supernatant was centrifuged again at
16 100 g for 30 minutes at 4°C. Pellets from both centrif-
ugations were combined. The high-speed supernatants
were stored separately from the pellets at -80°C.
Protein profiling
After thawing, 10 μl of each gastric fluid sample was
applied to different chemical surfaces of ProteinChip
arrays (Ciphergen Biosystems Inc, California, USA): (a)
copper(II) Immobilized Metal Affinity Capture (IMAC3)
in the presence of 100 μl of 1 mol/L urea, 1 g/L 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesul-
fonate (CHAPS), 0.3 mol/L KCl, protease inhibitor cock-
tail (Roche Diagnostics, Mannheim, Germany), 50 mol/L
TrisHCl, pH 7.5; (b) Weak Cation Exchange (WCX2 and
CM10) in the presence of 100 μl of 50 mmol/L sodium
acetate, 1 g/L octyl glucopyranoside, protease inhibitor
cocktail, pH 5; (c) Strong Anion Exchange (SAX2) in the
presence of 100 μl of 50 mmol/L TrisHCl, 1 g/L CHAPS,
protease inhibitor cocktail, pH 8; and (d) Hydrophobic
Interaction (H50) in the presence of 100 μl of 5 mL/L tri-
fluoroacetic acid. After washing with 100 μl of the same
respective buffers, sinapinic acid was added to facilitate
desorption and ionization. The chips were analysed by
SELDI-TOF-MS (PBSII, Ciphergen Biosystems Inc). Can-
cers and controls were intermingled and run concurrently
on the same chip and on multiple chips to minimize chip-
to-chip variation.
The gastric fluid pellets were resuspended in 25 μl of 6
mol/L guanidine thiocyanate, 5 g/L octyl glucopyrano-
side, 0.1 mol/L Hepes pH 7, and 100–200 μl of 9 mol/L
urea, 2 g/L CHAPS, 50 mmol/L TrisHCl, pH 7.5 by vortex-
ing for 45 minutes at 4°C. After centrifugation at 20 000
g for 5 minutes, 10 μl of the extract was applied to Protein-
Chip arrays as described above.
A retentate map was generated in which individual pro-
teins were displayed as separate peaks on the basis of their
mass to charge ratio. Data of the proteomic spectra were
analyzed by Ciphergen Express Data Manager Software
with Pattern Track and two-way hierarchical clustering
algorithm. Aligned peaks with signal to noise ratios above
3 were normalized by total ion current. Proteomic fea-
tures were further analyzed using the significance analysis
of microarrays (SAM) software from Stanford University.
The package was designed to address problems specific to
microarray data analysis (signal to noise ratio variance dif-
ferent from gene to gene, large number of data points
from a small number of samples) but we found it to be
applicable to proteomic data analysis as well. The algo-
rithm of the software was described by Tusher et al. [16].
In brief it defined a metric called the relative difference for
measuring the difference between two or more groups of
data in place of the p value. It employed a variation of the
bootstrapping method and repeatedly divided a given
data set (spectra containing the proteomic features in this
study) randomly into two groups to calculate the relative
difference for each of the permutations. The number of
permutations was set to be 1000 in this study and the soft-
ware computed 1000 relative difference values for each
proteomic feature. The relative difference of the particular
grouping of interest (observed relative difference) was
compared to the average relative difference from all the
permutations (expected relative difference) of each fea-
ture and the feature was judged to be up- or down-regu-
lated according to whether its observed relative difference
was greater or smaller than its expected relative difference
by some threshold. The software estimated a false discov-
ery rate (also defined in reference [16]) for each threshold
value that provided an indirect means to set the cutoff.
The markers identified by this method were statistically
significant. The false discovery rate was set to be less than
0.05 in this study.
To validate the markers identified by SAM, a second batch
of 53 blinded samples were added to the data set for hier-
archical clustering using the Ciphergen Express Data Man-
ager software. While the known samples used by SAM to
select the markers were expected to perform well in the
clustering, the blinded samples were included to test howBMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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well the markers generalize to unknown samples. The
results of the clustering were simply compared against the
true identity of the samples and no advanced classifica-
tion method or any other software was used in the valida-
tion.
Biomarker identification
Gastric fluid proteins were fractionated by anion exchange
chromatography (Q HyperD, Ciphergen Biosystems Inc.),
using stepwise changes in pH for elution. Proteins in the
50 mmol/L TrisHCl, 1 g/L octyl glucopyranoside, pH 8
eluants were further purified on a cation exchange array
(LWCX30) using 50 mmol/L sodium acetate, 1 g/L octyl
glucopyranoside, pH 5 as binding and washing buffer.
After addition of alpha-cyano-4-hydroxycinnamic acid
energy absorbing molecules (Ciphergen Biosystems Inc.),
the retained proteins were analyzed by PBSII and Q-TOF
(Waters/Micromass) equipped with a ProteinChip Inter-
face (PCI 1000, Ciphergen Biosystems Inc). Proteins were
characterized by MS/MS fragmentation and identification
was done by database search with Mascot (Matrix Science
Ltd., London, UK).
Biomarker validation
This was performed in a third set of gastric fluid samples
taken from benign gastric and gastric cancer patients. Each
freshly collected sample was processed to remove solid
debris and to concentrate the protein content as follows.
After adding phenylmethanesulfonyl fluoride to a final
concentration of 0.2 mM, the sample was centrifuged for
15 minutes at 500 g and 4°C. Protease inhibitors (Com-
plete Mini™, Roche Applied Science, Indianapolis, IN,
USA) were added to the supernatant followed by centrifu-
gal membrane filtration at 2 900 g and 15°C (Amicon
Ultra-4 centrifugal filter device, 5 000 nominal molecular
weight limit; Millipore, Billerica, MA, USA) until the sam-
ple was reduced to 10 – 20% of its original volume. Total
protein concentration was determined by the 2-D Quant
Kit (Amersham Biosciences, Pisctaway, NJ, USA). Pep-
sinogen C and alpha-defensin 1–3 concentrations were
determined by enzyme-linked immunoassay (ELISA)
using kits from Alpco Diagnostics (Salem, NH, USA) and
Hycult biotechnology b.v. (Uden, The Netherlands),
respectively. Each processed sample was assayed in dupli-
cate for pepsinogen C and defensin levels using the sup-
pliers' protocols. Samples for pepsinogen C assay were
pre-diluted 120-fold. Concentrations of pepsinogen C
and alpha-defensin 1–3 were derived by reference to their
respective standard curves and expressed as ng (pepsino-
gen C) or pg (defensin) per microgram of total gastric
fluid protein.
Helicobacter pylori
The presence of H. pylori in stomach tissues was identified
by visualization of spiral microorganisms in histology sec-
tions and/or by immunohistochemistry. Four-micron tis-
sue sections were de-waxed in xylene and decreasing
grades of ethanol. Antigen retrieval was by heating in cit-
rate buffer, pH 6.0. The primary antibody against H. pylori
(1:50 dilution; DAKO A/S, Glostrup, Denmark) was fol-
lowed by the secondary antibody polymer link (Envision
Chem Mate, DAKO) and visualized using diaminobenzi-
dine as chromogen.
Results
Multiple up- or down-regulated protein biomarkers in
gastric cancer were discovered in gastric fluid. A represent-
ative proteomic map of gastric fluid is shown in Figure 1.
It is a gel view of a mass spectrum showing gastric fluid
proteins selectively bound to immobilized copper(II)
metal ion in the molecular weight range of 1500 Da to
6000 Da. Significant protein markers found to be down-
regulated in cancer gastric fluid (p < 0.01) are indicated by
arrows.
A representative proteomic map of gastric fluid pellet
extract is shown in Figure 2. Proteins were selectively
bound to a cation exchange array surface. Significant pro-
tein markers found to be up- or down-regulated in gastric
cancer fluid pellet (p < 0.01) are indicated by arrows.
Average CV (coefficient of variation; cumulative for 10–15
major gastric fluid peaks per spectrum, n = 8) for immo-
bilized copper(II) ProteinChip array (IMAC3) was 12.8%,
for cation exchange array (WCX2) was 15%, for anion
exchange array (SAX2) was 17.3%, and for hydrophobic
interaction chip (H50) was 13.6%. These CV values are in
line with reproducibility assessment in the SELDI litera-
ture [17,18].
By SAM analysis of all proteomic features (total number of
features 41 800, average number per retentate map 314)
in gastric fluid and pellet extract, 46 proteomic features
were found to be significantly down-regulated in gastric
cancer and 60 proteomic features were significantly up-
regulated in gastric cancer. (Data from different condi-
tions, e.g., fluid and pellet as well as different surfaces,
were simply aggregated together as distinct features for
SAM. Markers reported by SAM in both pellet and super-
natant fractions were manually identified and represented
only once in the list after they were deemed biologically
significant). Significantly down-regulated markers
included 1884, 2428, 2594, 2840, 4050, 11720, 13700
Da; significantly up-regulated markers included 1761,
1831, 3372, 3443, 3605, 5160, 6780 Da. (Most of the sig-
nificant markers were discovered on WCX2 and IMAC-
copper(II), followed by SAX2). Based on the 106 signifi-
cantly different proteomic features (Additional file 1),
two-way hierarchical clustering analysis (two-dimen-
sional complete linkage) was performed. Most of the gas-BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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tric cancer cases were clustered together to form a
distinctive group (Figure 3 and Additional file 2). Princi-
pal component analysis of the same data also revealed
that cancer and benign samples could be well separated
into two groups, with 2 false negatives (representing
duplicate analysis of the same case) and 9 false positives,
respectively (Figure 4). One gastric cancer fluid sample
(from a case of stage I poorly differentiated gastric adeno-
carcinoma) clustered among non-cancer samples; all the
other 4 early stage (stages 0 and I) patients correctly clus-
tered with samples from 14 patients with stage II – IV gas-
tric cancer, giving an overall diagnostic sensitivity of 95%
(18/19 gastric cancer patients) on the training set.
Nine of 36 non-cancer samples in the training set clus-
tered with the cancer samples (specificity 75%). Of these,
1 had a dysplastic adenomatous polyp – a precancerous
lesion [19]. Among the other 8 patients, 6 had clinically
directed biopsies that revealed intestinal metaplasia in 4
patients (67%). Eight non-cancer patients whose gastric
fluid protein profiles clustered in the normal group also
had clinically directed mucosal biopsies that showed
intestinal metaplasia in only 2 patients (25%). A review of
1000 consecutive gastric biopsies performed for all indica-
tions showed an overall prevalence of intestinal metapla-
sia in the Singapore General Hospital during the study
period of 30%. This contrasts with the prevalence of at
least 67% of intestinal metaplasia among clinically
benign cases whose proteomic profiles clustered more
closely with gastric cancer cases than with other normals,
consistent with intestinal metaplasia being an intermedi-
ate state in the transition of normal gastric epithelium to
gastric adenocarcinoma. Accurate identification of intesti-
nal metaplasia by endoscopy is known to be inaccurate
[20]. Thus, a gastric cancer-type proteomic fingerprint is
possibly a sensitive indicator for the presence of this pre-
malignant lesion among patients clinically diagnosed as
having benign gastric disorders.
Gastric cancer patients in the training set were signifi-
cantly older (mean age 67.7 years) than patients with
benign gastric conditions (mean age 56.6) (p = 0.0062).
Expression difference map of gastric fluid on copper(II) immobilized metal affinity capture ProteinChip array (IMAC3) Figure 1
Expression difference map of gastric fluid on copper(II) immobilized metal affinity capture ProteinChip array 
(IMAC3). Arrows indicate protein biomarkers significantly different in expression level between the two groups of samples.BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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To address the possibility that protein profiles were
related to age or ethnicity, we re-analyzed data of the sub-
set of Chinese patients above 55 years of age. This resulted
in 1/17 cancers misclassified (the same tumor that was
misclassified when all 19 cancers were analyzed; sensitiv-
ity 94%) and 4/17 controls misclassified (the same 4 con-
trols that were among the 9 misclassified benign cases;
specificity 76.5%).
We next tested the actual performance of proteomic pro-
files in distinguishing cancer from benign samples in a
second series of 53 blinded gastric fluid and pellet extract
samples (24 gastric cancers and 29 benign gastric disor-
ders) (Additional file 3). Twenty-one of 24 gastric cancers
were correctly identified (sensitivity 88%) and 2 of 29
benign samples were wrongly classified (specificity 93%)
(Figure 5).
Selected proteomic markers (based on significance score
determined by SAM) were semi-purified on ProteinChip
arrays and identified directly on spots by collision-
induced dissociation sequencing (Figure 6). Several of the
significantly down-regulated markers in cancer patients
shown in Figures 1 and 2, 1881.9 Da, 2041.0 Da, 2188.1
Da and 2387.3 Da, were identified to be pepsinogen C
and pepsin A activation peptide fragments (Table 1). The
up-regulated triplet markers in cancer patients shown in
Figures 2, 7 and Additional file 4 were identified to be
alpha defensin-1,2,3. Intensity scatter plots show highly
significant differences in the mean intensities of defensin
and pepsin fragment between benign control and gastric
cancer fluid samples (p = 0.003 and 0.00002, respectively)
(Figure 8). Using ELISA specific for pepsinogen C, we con-
firmed significantly lower concentrations in gastric cancer
fluids (11.9 ± 0.1 ng/μg total protein; mean ± s.e.m. n =
6.) compared to benign samples (21.5 ± 1.4 ng/μg total
Expression difference map of gastric fluid pellet extract on cation exchange ProteinChip array (WCX2) Figure 2
Expression difference map of gastric fluid pellet extract on cation exchange ProteinChip array (WCX2). 
Arrows indicate protein biomarkers significantly different in expression level between the two groups of samples.BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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protein. n = 23) in a third sample set (p = 0.0126; Stu-
dent's unpaired two-tailed t test). ELISA performed on the
same sample set for defensin levels showed higher con-
centrations in gastric cancer samples (63.4 ± 9.2 pg/μg
total protein; mean ± s.e.m. n = 6) than in benign samples
(46.2 pg/μg total protein; mean ± s.e.m. n = 23) ((p =
0.0654; Student's t test).
Discussion
Our data suggest that the spectral profile of unfractionated
gastric fluid could be a useful adjunct for cancer diagnosis
and detection of early stage disease, when combined with
clinical gastroscopy. Most recent attempts at identifying
protein biomarkers for gastric cancer have investigated
serum [21-29] and tissue [24,30-37], and have increas-
ingly used mass spectrometry. Older reports of serological
Expression difference map of gastric fluid and pellet extract proteins of training set samples on four ProteinChip arrays, dis- played in two-way hierarchical clustering Figure 3
Expression difference map of gastric fluid and pellet extract proteins of training set samples on four Protein-
Chip arrays, displayed in two-way hierarchical clustering. Significant proteomic features are displayed vertically. The 
intensity of the grayscale indicates the degree of relative protein level, higher or lower than the median value. Patient cases are 
presented horizontally; most gastric cancer patients are tightly clustered together. This figure shows the upper quartile of the 
full image (please see Additional file 2 for the full image).BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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assays of individual known tumor markers e.g. CEA, CA
19-9, CA 72-4, CA242 and TAG-72, have generally low
sensitivity (<50%) [38-41]. Moreover, there is substantial
cross-positivity of these tumor markers in non-gastric can-
cers e.g. raised CEA and MG7-Ag levels are common in
colorectal cancer, cholangiocarcinoma, pancreatic carci-
noma, and even in healthy controls [40,23]. Not surpris-
ingly, such serum tumor markers have no established role
in gastric cancer diagnosis and screening, although they
may serve as prognostic indicators and early markers of
recurrent disease following gastrectomy [39,41,42].
We chose to examine proteomic profiles of gastric fluid
for disease biomarkers because it seemed likely that per-
turbed gastric protein secretion in malignant and pre-
malignant states, coupled with the possible presence of
exfoliated cancer cells, could generate distinctive pro-
teomic profiles. As in the search for serum biomarkers,
several groups have investigated the diagnostic utility of
known tumor markers in gastric juice. Neither CEA nor
CA 19-9 positivity in gastric fluid has demonstrated diag-
nostic accuracy [43-46]. Alpha-1 antitrypsin in gastric
juice has recently been reported as a gastric cancer biomar-
ker [47,48].
Principal component analysis plot of proteomic features of training set samples Figure 4
Principal component analysis plot of proteomic features of training set samples. A single plane (denoted by the 
black line) divides the samples into two groups with 1 false negative (shown in duplicate spots) and 9 false positives.BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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Expression difference map of gastric fluid and pellet extract proteins of validation set samples on four ProteinChip arrays, dis- played in two-way hierarchical clustering Figure 5
Expression difference map of gastric fluid and pellet extract proteins of validation set samples on four Protein-
Chip arrays, displayed in two-way hierarchical clustering. Significant proteomic features are displayed horizontally. The 
intensity of the red or green colours indicates the degree of relative protein level, higher or lower than the median value. 
Patient cases are presented vertically; most gastric cancer patients are tightly clustered together.BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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Our approach to developing a sensitive method for gastric
cancer diagnosis differed from previous studies in three
ways. First, we chose a biological sample that was organ-
specific (i.e. endoscopically aspirated gastric fluid) rather
than systemic (i.e. serum), reasoning that the molecular
features would more likely be disease-specific. Second,
mass spectrometry enabled us to take an unbiased discov-
ery-based approach. Third, our data generated profiles of
multiple proteomic markers that are increasingly regarded
as having higher sensitivity and specificity than single
tumor markers [49,50]. For gastric cancer, combining
even 2 or 3 tumor markers achieved better diagnostic
accuracy compared to a single marker alone [38,40].
Protein fingerprints of gastric fluid from gastric cancer
patients showed a total of 106 proteomic features that
were significantly up- or down-regulated (Additional files
1 and 3). Two prominent markers were selected for iden-
tification by MS/MS. Pepsinogen A and pepsinogen C acti-
vation peptides were down-regulated in gastric fluids
removed from stomachs with histologically confirmed
adenocarcinomas. A study of cryostat sections of gastric
cancer has also reported significant down-regulation of
pepsinogen C, identified by MS/MS, in tumor tissue [51].
Reduced pepsinogen levels in blood and tissue are a well-
known consequence of multifocal chronic atrophic gastri-
tis, a histopathological condition which increases the risk
Table 1: Peptide sequences identified by MS//MS
Peptide m/z Sequence Protein Match Mowse† score Mowse score with significant homology
2386.29 FLKKHNLNPARKYFPQWKA Pepsin A activation peptide 35 >28
2187.12 FLKKHNLNPARKYFPQW Pepsin A activation peptide 18 >26
2040.03 LKKHNLNPARKYFPQW Pepsin A activation peptide 28 >26
1775.95 FLKKHNLNPARKYF Pepsin A activation peptide 47 >26
1628.84 LKKHNLNPARKYF Pepsin A activation peptide 40 >28
1880.92 LRTHKYDPAWKYRF Pepsinogen C activation peptide 31 > 22
†Mowse score = -10Log(P), where P = probability that the match is a random event (P < 0.05) m/z, mass/charge
High-resolution mass spectrum of fractionated gastric fluid proteins on LWCX30 ProteinChip array obtained on a QTOF  equipped with a PCI1000 interface Figure 6
High-resolution mass spectrum of fractionated gastric fluid proteins on LWCX30 ProteinChip array obtained 
on a QTOF equipped with a PCI1000 interface. Boxed peaks were subjected to fragmentation analysis by collision-
induced dissociation MS/MS.BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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of developing intestinal-type gastric cancer [52]. However,
chronic atrophic gastritis itself is not gastric cancer. A pro-
spective 10-year longitudinal study determined that <3%
of patients with this lesion progress to gastric cancer [53],
while in another prospective series, 49% of severe chronic
atrophic gastritis actually regressed to less advanced
lesions when followed over 5 years [54]. Hence, although
serum pepsinogen levels have been intensively investi-
gated as a cost-effective serological biopsy for non-inva-
sive gastric cancer screening, it has low positive predictive
value – (0.77%–1.25%) in general population studies and
15% in selected patients [55].
We identified a prominent up-regulated marker as alpha-
defensin 1–3. Immunohistochemical staining of gastric
adenocarcinoma tissues showed that alpha-defensin
expression was restricted to infiltrating neutrophils, and
was absent in normal and malignant gastric epithelial
cells (data not shown). Alpha-defensin overexpression
from intra-tumoral neutrophils has also been reported in
oral carcinomas by peptide sequencing and immunohis-
tochemistry [56,57]. Association of defensin expression
with cancers is consistent with the role of chronic inflam-
mation in oncogenesis. Expression of alpha-defensins 1–
3 was higher in colorectal cancer than in normal colon
[58,59], and correlated with tumor invasiveness in blad-
der cancer [60]. Using SELDI TOF mass spectrometry,
alpha-defensins 1 and 2 were among five prominent pro-
teins in urine samples of patients with transitional cell
bladder cancer [61]. Neutrophil defensin has also been
identified in the proteomic signatures of ovarian and
breast cancers [62,63].
Our data show that protein fingerprinting of gastric fluid
achieves high sensitivity and specificity because it does
not rely on a single marker. Multivariate analysis of a mul-
timarker panel of both gastric fluid and exfoliated cellular
proteomes has revealed a composite pattern of up- and
down-regulation of multiple components to generate a
highly specific and sensitive diagnostic method for gastric
cancer, including early stage disease. The protein profiles
in this study were independent of age and ethnicity, and
performed well in correctly identifying whether gastric
fluid was obtained from a malignant or benign source
(sensitivity 88%; specificity 93%) when tested independ-
ently against blinded samples. Combining data from
training and validation sample sets, the gastric cancer pro-
teomic signature had a positive predictive value of 0.80.
Most previous biomarker discovery studies have focused
on a limited number of markers [21,23-26,38-41] and few
have approached the diagnostic accuracy of this study.
Relying on a single biomarker has several disadvantages.
Individual markers are, in general, not very powerful in
classifying disease from healthy controls. A biofluid study
of bladder cancer markers using SELDI TOF mass spec-
trometry found that detection rates with single markers
were significantly improved by biomarker combinations
and clusters [61]. Our analysis confirms this experience.
Thus, although the mean albumin level in gastric cancer
fluid was significantly different from controls (p = 0.005),
only 8 out of 19 cancer patients in the training set showed
such elevation (data not shown), whereas transferrin and
alpha1-antitrypsin levels were upregulated in an even
smaller number of patients and were not significantly dif-
ferent from the general patient population (p > 0.1) (data
not shown). Furthermore, many cancers share the same
markers e.g. CEA, CA19-9, transferrin and alpha1-antit-
rypsin [40,42,64].
High-resolution mass spectrum of gastric fluid proteins on  H50 ProteinChip array obtained on a QTOF equipped with a  PCI1000 interface Figure 7
High-resolution mass spectrum of gastric fluid pro-
teins on H50 ProteinChip array obtained on a QTOF 
equipped with a PCI1000 interface. This figure shows 
the up-regulated triplet markers in gastric cancer. Please see 
Additional file 4 for the full image.BMC Medical Genomics 2008, 1:54 http://www.biomedcentral.com/1755-8794/1/54
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Conclusion
Highly informative protein profiles for biomarker discov-
ery have been generated by high throughput analysis of
both gastric fluid and exfoliated cellular proteomes using
small sample volumes and simple sample processing.
Identification of pepsinogens A and C among prominent
down-regulated markers in gastric cancer fluid samples
strengthens the biological plausibility of the proteomic
signature we report for gastric cancer diagnosis. A future
large cohort study is needed to confirm these results. It
will be particularly important to incorporate multiple
mucosal biopsies at standard sites and closely follow up
patients with clinically benign gastric disorders but whose
proteomic profiles are cancer-like. Given the high curative
potential of early stage gastric cancer, documented false
negative gastroscopic diagnosis and the expense of endo-
scopic surveillance of all gastric ulcers, a test that provides
a pan-gastric molecular biopsy could be a clinically useful
supplement to conventional gastroscopy. Proteomic sig-
natures that distinguish benign from malignant disorders,
and identify early stage cancer and pre-malignant gastric
lesions with high sensitivity and specificity could make a
significant contribution to reducing mortality from the
second most common cause of global cancer deaths.
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